



## Quviviq™ (daridorexant) – New drug approval

- On January 10, 2022, [Idorsia announced](#) the FDA approval of [Quviviq \(daridorexant\)](#), for the treatment of adult patients with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance.
  - The FDA has recommended that Quviviq be classified as a controlled substance. The Drug Enforcement Administration (DEA) will assign the scheduling.
- Insomnia is the most common sleep disorder, affecting more than 25 million adults in the U.S.
- Quviviq is a dual orexin receptor antagonist, which blocks the binding of the wake-promoting neuropeptides orexins and is thought to turn down overactive wakefulness.
- The efficacy of Quviviq was evaluated in two randomized, double-blind, placebo-controlled, parallel-group studies. A total of 1,854 patients with insomnia were randomized to receive Quviviq or placebo once daily, in the evening, for 3 months. Primary efficacy endpoints for both studies were the change from baseline to month 1 and month 3 in Latency to Persistent Sleep (LPS) and Wake After Sleep Onset (WASO). LPS is a measure of sleep induction and WASO is a measure of sleep maintenance.
  - In study 1, doses of 25 and 50 mg Quviviq showed a statistically significant improvement vs. placebo on LPS and WASO at month 1 and month 3.
  - In study 2, Quviviq 25 mg showed a statistically significant improvement vs. placebo on WASO at month 1 and month 3.
- Quviviq is contraindicated in patients with narcolepsy
- Warnings and precautions for Quviviq include central nervous system-depressant effects and daytime impairment; worsening of depression/suicidal ideation; sleep paralysis, hypnagogic/hypnopompic hallucinations, and cataplexy-like symptoms; complex sleep behaviors; patients with compromised respiratory function; and need to evaluate for co-morbid diagnoses.
- The most common adverse reactions ( $\geq 5\%$  of patients treated with Quviviq and at an incidence  $\geq$  than placebo) with Quviviq use were headache, somnolence or fatigue.
- The recommended dosage range of Quviviq is 25 mg to 50 mg taken orally no more than once per night within 30 minutes of going to bed (with at least 7 hours remaining prior to planned awakening).
- Idorsia plans to launch Quviviq in May 2022 after controlled substance scheduling by the DEA. Quviviq will be available as 25 mg and 50 mg tablets.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2022 Optum, Inc. All rights reserved.